Relationship Between Serum Myostatin Level and Cardiovascular Calcifications in Chronic Kidney Disease Patients | ||||
| Al-Azhar International Medical Journal | ||||
| Volume 2024, Issue 12, December 2024 | ||||
| DOI: 10.58675/2682-339X.2806 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed Saad1; Alsayed Rashed1; Mohamed Ahmed 2; Mohamed Abo Ghabsha3; Mohamed Abd Elhakim1
| ||||
| 1Internal Medicine and Nephrology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt | ||||
| 2Diagnostic Radiology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt | ||||
| 3Clinical Pathology, Faculty of Medicine for Boys, Al-Azhar University, Cairo, Egypt | ||||
| Abstract | ||||
| Background: With its detrimental effects, including kidney failure, cardiovascular disease, and early mortality, chronic kidney disease(CKD) is a global public health concern. Aim and objectives: To evaluate serum myostatin levels and their association with cardiovascular calcifications in patients with chronic kidney disease. Patients and methods: A case-control study was conducted on 90 participants, and they were divided into three groups: Group A included 30 patients with chronic kidney disease; Group B include30 patients diagnosed with end-stage kidney disease on regular hemodialysis; and the control group included 30 apparently healthy individuals as a control group. Ages and sex were matched with the above groups. The patients were collected from the Nephrology Units, Department of Internal Medicine, Syed Galal University Hospital, Cairo, Egypt, from May 2023 to December 2023. Results: The results provide compelling evidence that myostatin plays a significant role in the pathophysiology of cardiovascular complications in CKD and ESRD patients. Conclusion: Serum myostatin was higher in CKD&ESKD patients than in the control group. A positive correlation between serum myostatin levels and cardiovascular calcifications suggests that myostatin could serve as a valuable biomarker for identifying CKD&ESKD patients at high risk for cardiovascular events. Monitoring myostatin levels might help in early detection and intervention, potentially improving cardiovascular outcomes in this population. Additionally, therapeutic strategies targeting myostatin pathways could be developed to mitigate cardiovascular complications in CKD patients. | ||||
|
Statistics Article View: 15 |
||||
